focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

30 Sep 2008 07:00

RNS Number : 6311E
ViaLogy PLC
30 September 2008
 



ViaLogy plc

Final results for the year ended 31 March 2008

London, 30 September, 2008: Vialogy PLC (AIM: VIY), the AiM-listed technology company, is pleased to report its final results for the year ended 31 March 2008.

Chairman's Statement

I am pleased to present the financial results for your Company for the year ending 31 March 2008 and to comment on progress during the year. It was a time of transformation for ViaLogy, as we moved from an organisation devoted exclusively to the research and development of our technology to a company where the emphasis of our work focussed on adapting the technology to provide products that suit customers' specific requirements. Inevitably this move towards commercialisation was costly in terms of time, manpower and money. The financial facts contained in the accounts for the year show minimal income and a net loss of £4.9 million. 

Our Products

During the year our scientists completed work on ViaLogy's first product, Sensor Policy Manager (SPM™). SPM is a remarkable enhancement in the world of safety and security, a technology that can adapt any kind of sensor to perform more efficiently and - most importantly - enable complete interoperability between sensors from different manufacturers. SPM transforms a collection of disparate sensors performing a variety of different tasks into an integrated, cohesive security system. Our second product, MicroSPM™, adds strength and distance to video sensor coverage.

To market the SPM products efficiently we decided to partner with a range of global and national commercial companies. ViaLogy's sales and technical teams have spent several months introducing and demonstrating the products to our potential partners. Because we are dealing with prestigious 'names', international businesses with envied reputations to protect, these partners insist on rigorous and prolonged testing of our products. This is an onerous and expensive process that is nevertheless essential if we are to be an accepted part of any major security installation. In each case ViaLogy has satisfactorily completed these proof-of-concept demonstrations.

In addition to the SPM products the ViaLogy team has refined our patented weak signal detection technology, Quantum Resonance Interferometry (QRI™), for two most exciting and potentially lucrative commercial applications. As you will read in the reports of Dr. Robert W. Dean, our Chief Executive Officer, and Dr. Sandeep Gulati, our Chief Technology Officer, we are working closely with companies in the oil and gas industry in two key areas. In Texas, field trials have commenced using ViaLogy technology aimed at vastly improving the strike rate of oil exploration drilling. Using another derivative of our QRI technology, proof-of-concept flights will be taking place to detect and plot the location and condition of buried oil and natural gas pipelines. Success of these pilot efforts should produce substantial and near-term cash flow for the Company.

Funding

The worldwide economic woes that prevailed during the year provided a difficult background to the Company's commercial activities. So, while our technology has been validated and approved for incorporation into a gratifying number of projects, a general reticence by customers to embark on capital expenditures and expansion has lead to cash flow pressures for us. 

In June 2007 the Company raised £4.4 million (£4.316 million net of costs) by way of a placing of 55 million new ordinary shares at a placing price of 8 pence per share. In addition the participants received one warrant for every two shares purchased in the placing. Each warrant entitles the holder to purchase an additional share at 10 pence per share at any time before October 2009. In August 2008 the Company raised a further £1.8 million (£1.739 million net of costs) by way of a placing of 45 million new ordinary shares at a placing price of 4 pence per share. In addition, subject to shareholder approval at the Annual General Meeting, the participants will receive one warrant for each share purchased in the placing. Each warrant will entitle the holder to purchase an additional ordinary share at 5 pence per share at any time before October 2011.

Acrobot

ViaLogy directors have again decided to retain the Company's holding in The Acrobot Company. During the year Acrobot launched its first two products, Planner and a Navigator, with the capability to perform orthopedic procedures including unicondylar knee replacement and total hip replacement. To date well over 100 surgical procedures have been successfully undertaken using these products. A distribution strategy is now in place in the UK and arrangements are being made for launches in Europe and the US.

My thanks

I want to record my sincere thanks to the ViaLogy team, the 35 men and women in our Pasadena, California, offices who have worked long hours, often including weekends, to transform our unique technology into real products. They are a brilliant bunch of people. In particular I want to thank Bob Dean, who took over the reins of the Company at a critical time and is guiding us towards success.

Terry Bond

Chairman

29 September 2008

Chief Executive Officer's Report

The year ending 31 March 2008 marked the full productisation of ViaLogy's flagship product, SPM. Having completed some of the lengthy, but necessary, certifications required for insertion into US Government programs, ViaLogy has now deployed SPM and is actively pursuing contracts with key partner firms Cisco Systems, Axia Supernet, Coleman Technologies, Scientific Applications International Corporation (SAIC) and others. Three "permanent" demonstrations are up and running at Cisco's Washington, DC, Center of Excellence; at three Axia sites in Alberta (preparatory to a major joint bid to the Alberta government for an automated air quality monitoring system); and in Los Angeles County as a key element in a proposed Department of Homeland Security radiation warning and management system. Such pilot programs are a necessary phase in market acceptance and in any sale of our software products for operational use in enterprise grade applications. Our progress in building an effective front-end sales effort has not been as rapid as we would have wished but we now have in place a ten-person national sales network that should show real results in the coming months. Key tasks are to keep our software products' development moving forward with our markets, which calls for continuing research and development (R&D) investment, and establishing sales and subcontractor relationships with other large system integrators. I want to stress that in SPM and its planned future versions the Company has what we believe to be a singularly capable, core sensor integration capability in the growing Physical Security Information Management (PSIM) market.

Beginning this year, ViaLogy also launched major efforts in two additional key marketsenergy and life sciences, to productise its core, unique and proprietary signal processing technology, QRI. Perhaps the most exciting energy application is in the oil discovery area where we have introduced QuantumRD™, an oil reservoir discovery technology that interprets seismic data and can more accurately locate and define the capacity of oil and gas deposits, and maximize extraction. We have partnered with Texas-based Atascosa Exploration. On the basis of ViaLogy's analysis of raw 2D and 3D seismic data Atascosa has repositioned planned drill sites, acknowledged ViaLogy's discovery of a major unknown oil reservoir located on one of their existing leases, and granted ViaLogy a 5% working interest as payment in two wells going forward. Subject to the accuracy of ViaLogy's predictions and the price of oil, revenue from these two sites could total $8 million  for your company over the period of extraction. The results from the first "ViaLogy well" are due in October 2008, and should provide the basis for market acceptance and accelerate the growth of this part of our business.

The second effort underway to bring another QRI-based product to a high-demand energy market is QSUB™, a technology to analyse data from airborne synthetic aperture radar (SAR), and light detection and ranging (LIDAR) sensors to precisely geolocate and monitor the health of buried gas and oil pipelines. There are almost 3 million kilometres of buried pipeline in the US alone; current methods for accurately locating pipelines are largely manual and costly. ViaLogy has teamed with Advanced Spatial Technologies Field Services (ASTFS), a Texas pipeline consulting firm with critical domain expertise, to conduct aerial flyover pilot missions this autumn. We have commitments from three major pipeline companies for future buys of data following successful proof-of-concept demonstrations. We anticipate cash flow from this business line in the next ViaLogy fiscal year. Assuming the pilot results are successful our agreement with ASTFS guarantees us a minimum of $1 million in the first year of use of QSUB, and $26 million minimum over the five year life of the agreement. 

In the medical devices market ViaLogy has teamed with Sensovation, a German firm that develops and produces medical diagnostic devices, to introduce an application of QRI to the pathology market. QRI can simplify the design of such devices, thereby lowering the cost and price point to enable broader market penetration, and thus permit use of devices at the point of care. ViaLogy has now accomplished a proof-of-concept demonstration of this technology and is developing its go-to-market strategy.

ViaLogy is now single-mindedly focused on bringing its technologies to market as high-demand products. We are positioned in three market areas, PSIM, energy, and life sciences. While these markets are not immune to current financial, business and customer uncertainties, they are certainly more resistant than other consumer-dependent markets. Nevertheless, while these markets are likely to remain healthy in a period of downturn, gaining credibility for new products takes some time and requires that certain industry standards be demonstrated. We are well along in these processes, and I believe we will have a number of successes to report to you in the coming months.

Dr. Robert W Dean

Chief Executive Officer

29 September  2008

 Chief Technology Officer's Review

During the fiscal year, we matured, upgraded and branded our products, completed pilots, demonstrated value-proposition to our customers, and we now are moving to operational deployments. The Company launched market-focused SPM, QuantumRD and QSUB product and service offerings with strategic partners in three high growth vertical markets. 

Physical Security Information Management 

PSIM is the rapidly growing technology market that integrates physical security infrastructure, unified communications (voice, video and sensors), mobility and operations with emergent enterprise IT architectures. It is a system-of-systems solution that incorporates products from more than one manufacturer to address the breadth and depth of functionality required by customers. 

SPM is a scaleable, open, standards-based software and service platform for cost-effective large-scale sensor integration, aggregation, and interoperability within PSIM. SPM software is sensor agnostic; it combines input from multiple networked sensors to provide complete, real-time actionable assessment and policy-based responses. Remote monitoring, assessment, training, warning and response design are at the core of PSIM. SPM's powerful built-in policy engine and toolkit for enterprise users to rapidly design, test, and deploy sensor-based policies should accelerate ViaLogy's selection as partner of choice for PSIM integrators.

 

SPM is a core sensor integration and fusion engine for Cisco Open Platform for Safety and Security (COPSS), launched in the US in April 2008 and in Europe in June 2008. Cisco is positioning COPSS as a one-stop solution that combines video, voice, sensor and mobility for all safety and security operations and business continuity applications in federal, enterprise and public sectors.

Coleman Technologies has selected SPM for the Coleman Incident Response System (CIRS) platform targeted at state and local agencies for public safety and PSIM applications.

ViaLogy is certified by Lenel Systems International Inc, a United Technologies Fire and Security Division's Open Alliance partner, to integrate sensors into Lenel's enterprise video management and access control platform.

Canada-based Axia NetMedia Corporation has selected SPM as a managed services delivery partner for offering sensor-based services over its Alberta province-wide broadband network, SuperNet. ViaLogy and Axia recently installed a pilot system for 24/7 air-quality monitoring as a first offering for public agencies.

Bruker-Daltonics, one of the largest chemical, biological, radiological, nuclear and explosive detection (CBRNE) sensor manufacturers  has chosen SPM as an integration platform for its broad family of homeland security focused sensors.
ViaLogy and Safe Environment Engineering have completed an SPM pilot for integrated CBRNE monitoring within LA County facilities for the US Department of Homeland Security's program to instrument cities on the US West Coast.
One of the largest US defence integrators has subcontracted with ViaLogy to demonstrate scaleable integration of perimeter intrusion surveillance radars with other military base security sensor infrastructure to meet real-time base security requirements.
SPM is among the first software infrastructure products to be certified as compliant to US Federal Emergency Management Agency's National Incident Management System (NIMS) interoperability standards. 

MicroSPM®

First-stage development is complete on this is high-performance, small form factor hardware platform for fully autonomous sensor processing at the network edge. MicroSPM's first PSIM offering is real-time surveillance using high definition (HD) digital video cameras. The MicroSPM platform addresses three major trends within the global surveillance industry: increasing adoption of network addressable digital video camera and thermal imagers; the need for real-time autonomous processing by moving the policy execution and the intelligence to the network edge; and the accelerated migration to Internet Protocol version 6 (IPv6).

 

ViaLogy is currently piloting MicroSPM at Cisco's Center of Excellence in HerndonVirginia, as a COPSS building-block for real-time video surveillance.

ObjectVideo and ViaLogy announced a collaboration to deploy OVServer video analytics software on MicroSPM.

Energy 

ViaLogy is launching two applications in the Energy market: QuantumRD services for oil and gas reservoir discovery, sizing and development; and QSUB aerial survey services for buried oil and gas pipeline accurate geolocation and condition assessment. These applications will be implemented with strategic partners who offer significant domain expertise, customer relationships and operational depth.

QuantumRD is computational technology, now in operational pilot use, to fundamentally improve the petroleum industry's ability to accurately locate, characterise and measure hydrocarbon deposits. This is a breakthrough computational software platform for detecting, predicting and monitoring hydrocarbons based on a systematic fusion of geoseismic data, well logs, production history and reservoir flow model. QuantumRD delivers operational cost-savings by: 

identifying and positioning hydrocarbon deposits

permitting oil recovery using the minimum number of wells

optimising infill well locations

QuantumRD works with existing 2D, 3D and 4D geoseismic datasets to identify and predict heterogeneity, lithology and fluid types (oil, gas and water). For reservoir discovery, QuantumRD fuses seismic, electroseismic and geological datasets from existing sensors, to characterise reservoir boundaries, fluid sizing and porosity. QuantumRD is derived from the Company's patented weak signal detection technology QRI. It enables prediction and quantitation of porosity (a key reservoir indicator) by exploiting subtle changes in seismic noise across the underlying lithology. Over the last 20 years the geoseismic industry has spent large sums developing migration, seismic inversion and stacking algorithms that cancel or average out seismic noise. While this may suffice for large hydrocarbon traps it misses and mischaracterises small hydrocarbon-rich formations. QuantumRD is geology agnostic, and applicable to both on-shore and off-shore prospects. To optimize recovery, ViaLogy can characterise changes in seismic response between multiple seismic surveys in response to production, and map these seismic changes to variations in saturation. 

In June 2008 ViaLogy announced that it had entered into an agreement with a Texas-based oil and gas exploration and production company, Atascosa Exploration LLC, of San Antonio, to apply QuantumRD to analyse three reservoir prospects at varying depths and lithology to more accurately definthe extent and porosity prior to the commencement of drilling. Recently, ViaLogy and Atascosa disclosed that with reference to the first prospective Texas drilling site, the QuantumRD analysis confirmed the location of an oil trap, and mapped its size, shape, and predicted porosity. Drilling will be completed in October 2008.

QSUB services platform offers a globally deployable, end-to-end aerial field service for buried oil and gas pipeline geolocation and degradation assessment. In addition to deploying the most advanced commercially available aerial sensors, QRI technology is the underlying computational engine for the platform. QSUB delivers smart fusion of airborne electromagnetic data from:

ground-penetrating synthetic aperture radar (SAR);

high frequency light detection and ranging sensor (LIDAR)

magnetic sensor; and 

orthophotography.

 

This will determine energy pipeline depth, extent of ground cover and geolocation coordinates. QSUB aims to provide pipeline condition and identify potential leaks by exploitation of wideband electro-optical sensors from a height of 2,000 to 10,000 feet above ground level.

In a departure from traditional energy infrastructure aerial survey offerings which are focused on data acquisition and best-efforts processing, ViaLogy intends to provide quantitative data quality and accuracy guarantees. Results will be delivered to the pipeline companies in the industry-standard Geographic Information Systems (GIS) and engineering formats so that they can be directly incorporated in operations and maintenance planning systems.

To date, survey companies have been unable to exploit SAR and LIDAR to offer standoff detection for pipeline buried between one and three metres below ground. They have been limited to aerial photography for assessing construction in the proximity of pipelines and any significant ground cover movements. SAR performance has been limited by requiring multiple ground conductivity measurements to compensate for soil moisture variability. ViaLogy signal processing aims to eliminate the need for multiple expensive ground-based conductivity measurements.

 

ViaLogy has partnered with Texas-based Advanced Spatial Technologies Field Services to pilot and market the service in North America A proof of concept flight is planned for October when QSUB will be fully tested. Pilot success will open the possibility for broad ranging applications that include inspection of thousands of miles of narrow bore sub-sea oil gathering and transportation lines, underground petrochemical storage tanks, and the integrity of transportation infrastructure (subway tunnels). 

Dr. Sandeep Gulati

Vice President and Chief Technology Officer

ViaLogy PLC

29 September 2008

  

Consolidated income statement for the year ended 31 March 2008

Notes

2008

2007

£

£

Revenue

31,485

273,478

Cost of sales

407

8,410

--------

--------

Gross profit

31,078

265,068

Administrative expenses 

5,409,444

1,848,450

--------

--------

Loss from Operations

(5,378,366)

(1,583,382)

Finance costs

-

(353)

Finance income

119,985

106,373

Share of losses of associate

-

(526,481)

--------

--------

Loss for the year before  taxation 

(5,258,381)

(2,003,843)

--------

--------

Taxation

3

389,454

171,524

--------

--------

Loss for the year attributable to equity 

holders of the parent company

(4,868,927)

(1,832,319)

--------

--------

Loss per share

Basic  and diluted

4

(1.091)p

(0.523)p

 

Consolidated statement of changes in equity for year ended 31 March 2008

Statement of changes in equity for 2007

Share

Share 

Warrant

Foreign

Retained

Total

capital

premium

reserve

exchange

earnings

account

reserve

At 1 April 2006

3,112,222

7,639,013

-

-

(5,107,858)

5,643,377

Loss for year 

-

-

-

-

(1,832,319)

(1,832,319)

Reversal of previously 

equity accounted losses

-

-

-

-

2,467,890

2,467,890

Exchange differences arising on 

translation of foreign operations

-

-

-

20,075

-

20,075

--------

--------

--------

--------

--------

--------

Total income and expense 

recognised for the year

-

-

-

20,075

635,571

655,646

Arising on issue of shares

919,033

3,331,495

-

-

-

4,250,528

Share options expense

-

-

-

-

126,970

126,970

--------

--------

--------

--------

--------

--------

Balance at 31 March 2007

4,031,255

10,970,508

-

20,075

(4,345,317)

10,676,521

--------

--------

--------

--------

--------

--------

Statement of changes in equity for 2008

Share

Share 

Warrant

Foreign

Retained

Total

capital

premium

reserve

exchange

earnings

account

reserve

At 1 April 2007

4,031,255

10,970,508

-

20,075

(4,345,317)

10,676,521

Loss for year 

-

-

-

-

(4,868,927)

(4,868,927)

Exchange differences arising on 

translation of foreign operations

-

-

-

(456,469)

-

(456,469)

--------

--------

--------

--------

--------

--------

Total income and expense 

recognised for the year

-

-

-

(456,469)

(4,868,927)

(5,325,396)

Arising on issue of shares

556,481

3,511,341

-

-

-

4,067,822

Arising on issue of warrants

-

-

275,000

-

-

275,000

Share options expense

-

29,853

-

-

777,141

806,994

--------

--------

--------

--------

--------

--------

Balance at 31 March 2008

4,587,736

14,511,702

275,000

(436,394)

(8,437,103)

10,500,941

--------

--------

--------

--------

--------

--------

  Consolidated Balance Sheet as at 31 March 2008

2008

2007

£

£

Assets

Non current assets

Property, plant and equipment

99,343

51,730

Intangible Assets

10,148,333

11,649,759

Financial Assets

200,000

200,000

--------

--------

10,447,676

11,901,489

--------

--------

Current assets

Inventories

10,515

1,965

Trade and other receivables 

29,116

43,332

Cash and cash equivalents

2,190,050

1,197,855

--------

--------

2,229,681

1,243,152

--------

--------

Total Assets

12,677,357

13,144,641

--------

--------

Liabilities

Current liabilities

Trade and other payables

380,246

169,695

Non-current liabilities

Deferred tax liability

1,796,170

2,298,425

--------

--------

Total liabilities

2,176,416

2,468,120

Capital and reserves attributable to equity

holders of the Company

Share capital

4,587,736

4,031,255

Warrant Reserve

275,000

-

Share premium account

14,511,702

10,970,508

Foreign Exchange translation reserve

(436,394)

20,075

Retained Earnings

(8,437,103)

(4,345,317)

--------

--------

Shareholders' funds

10,500,941

10,676,521

--------

--------

Total equity and liabilities

12,677,357

13,144,641

--------

--------

Consolidated cash flow statement for the year ended 31 March 2008

2008

2007

£

£

Operating activities

Loss  before tax

(5,258,381)

(2,003,843)

Adjustments for :-

Share of associate

-

526,481

Finance income

(119,985)

(106,373)

Finance cost

-

353

  Depreciation

43,623

17,492

Amortisation

2,181,438

869,385

Share option expense

806,994

126,970

Foreign exchange movements

(4,076)

26,426

--------

--------

Cash from operating activities before changes in working capital

(2,350,387)

(543,109)

Reduction in trade and other receivables

14,216

1,023

Increase in inventories

(8,550)

(1,965)

Increase/(Reduction) in trade and other payables

210,551

(91,975)

Interest received

119,985

106,373

Interest paid

-

(353)

--------

--------

Cash generated from operations

(2,014,185)

(530,006)

Investing activities

Acquisition of subsidiary, net of cash acquired

-

(685,174)

Internally generated intangible asset

(1,245,207)

(350,286)

Acquisition of tangible fixed assets

(91,236)

(50,237)

--------

--------

(3,350,628)

(1,615,703)

Financing Activities

Cash inflow from issue of new shares 

4,427,143

-

Share issue costs

(84,320)

-

--------

--------

4,342,823

-

Decrease in cash and cash equivalents

992,195

(1,615,703)

Cash and cash equivalents at beginning of year

1,197,855

2,813,558

--------

--------

Cash and cash equivalents at end of year

2,190,050

1,197,855

--------

--------

  Notes forming part of the consolidated financial statements for the year ended 31 March 2008

1. Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (collectively IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the European Union ("adopted IFRSs"), and are in accordance with the IFRS as issued by the IASB. 

The financial statements have been prepared on a going concern basis as the Board believe the Group have adequate resources to continue in operational existence for the foreseeable future. 

2. Segmental analysis

The Group's primary and secondary formats for reporting segment information are shown below. The primary operations segment is based in the USA; the head office primary segment is based in the UK. The differing geographical locations being the secondary segment overlap completely with the differing nature of the business segments.

2008 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

31,485

-

-

31,485

--------

--------

--------

--------

Gross  Profit

31,078

-

-

31,078

Net Finance Income

-

-

119,985

119,985

Net Tax Credit

-

-

389,454

389,454

Net loss for the year

(3,954,573)

(1,423,793)

509,439

(4,868,927)

Segment assets

8,488,295

2,392,892

1,796,170

12,677,357

Segment liabilities

297,186

83,060

1,796,170

2,176,416

--------

--------

--------

--------

Costs to acquire plant property and equipment

91,236

-

-

91,236

Costs to acquire intangible assets

1,245,207

-

-

1,245,207

Depreciation and amortisation

2,223,949

1,112

-

2,225,061

Share based payments charged

-

806,994

-

806,994

--------

--------

--------

--------

All sales were to external customers.

2007 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

269,804

3,674

-

273,478

--------

--------

--------

--------

Gross  Profit

261,394

3,674

-

265,068

Net Finance Income

-

-

106,373

106,373

Net Tax Credit

-

-

171,524

171,524

Net loss for the year

(879,850)

(1,230,366)

277,897

(1,832,319)

Segment assets

8,022,101

2,824,115

2,298,425

13,144,641

Segment liabilities

95,102 

74,593 

2,298,425

2,468,120 

--------

--------

--------

--------

Costs to acquire plant property and equipment

48,694

1,543

-

50,237

Costs to acquire intangible assets

350,286

-

-

350,286

Depreciation and amortisation

885,996

882

-

886,877

Share based payments charged

-

126,970

-

126,970

--------

--------

--------

--------

All sales were to external customers.

 

 

3Taxation on profits from ordinary activities

2008

2007

£

£

Current tax credit

UK corporation tax and income tax of overseas operations on profits for the year

-

-

Adjustments for under/(over) provision in prior periods.

-

-

________

________

Deferred tax credit

Release of provision

(389,454)

(171,524)

________

________

Total tax credit

(389,454)

(171,524)

________

________

The reason for the difference between the actual tax credit for the year and the standard rate of

 corporation tax in the UK applied to profits for the year are as follows

2008

2007

£

£

Loss before tax

5,258,381

2,003,843

Expected tax charge based on the standard rate of corporation tax in the UK of 30% (2007 - 30%)

(1,577,514)

(601,153)

Expenses not deductible for tax purposes

768,108

245,632

Capital allowances for year in deficit/(excess) of depreciation

(74)

(74)

Exercise of share options

-

Increase in  carried forward

809,480

355,592

Deferred tax release 

(389,454)

(171,524)

________

________

Total tax credit for the year

(389,454)

(171,524)

________

________

The Group is required to estimate the income tax in each of the jurisdictions in which it operates. This requires an estimation of the current tax liability together with an assessment of the temporary differences which arise as a consequence of different accounting and tax treatments. These temporary differences result in deferred tax assets or liabilities which are included within the balance sheet. Deferred tax assets and liabilities are measured using substantially enacted tax rates expected to apply when the temporary differences reverse. Management judgement is required to determine the total provision for income tax. Amounts accrued are based on management's interpretation of country specific tax law and the likelihood of settlement.

Factors that may affect future tax charges

Deferred tax assets relating to UK revenue losses and UK capital losses of £1,875,540 and £1,934,399 respectively (2007: £1,437,457 and £1,934,399) have not been recognised as these losses can only be offset against future taxable profits and at present there is insufficient evidence to justify recognition. 

Deferred tax assets relating to US revenue losses of £1,042,762 (2007: £364,854) have not been recognised as these losses can only be offset against future taxable profits and at present there is insufficient evidence to justify recognition. In addition ViaLogy LLC may be entitled to further tax losses. The maximum amount of losses available is $6 million, however this is subject to an annual limitation which is estimated at $250,000 per year. At the balance sheet date the accrued potential losses claimable are estimated at $500,000 (2007 - $250,000).

4Loss per share

Basic

The calculation of earnings per share is based on the loss for the year of £4,868,927 (2007: loss £1,832,319) and on 446,268,077 (2007: 350,501,448) ordinary shares, being the weighted average number of ordinary shares in issue during the year.

Diluted

Diluted earnings per share dilute the basic earnings per share to take into account share options and warrants. The calculation includes the weighted average number of ordinary shares that would have been issued on the conversion of all the dilutive share operations and warrants into ordinary shares. 65,580,702 options (2007: 35,553,804) and 31,193,654 (2007: 3,693,654) warrants have been excluded from this calculation as this would reduce the loss per share.

5Post Balance Sheet Events

 The Group raised £1.8 million (£1.749 million net of expenses), via a private placing of 45 million shares at 4 pence per share on 19 August 2008.

6. Report and accounts

The Company's report and accounts for the year ended 31 March 2008 will be available on www.Vialogy.com today and will be posted to shareholders on 30 September 2008. Photocopies of the report and accounts for the year ended 31 March 2008 are available from the Company's registered address.

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications 

Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR IFFLLAEIAFIT
Date   Source Headline
11th Sep 20237:00 amRNSCancellation - Yourgene Health plc
11th Sep 20237:00 amRNSDe-listing and cancellation of trading of Shares
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
8th Sep 202311:23 amRNSScheme of Arrangement becomes Effective
8th Sep 20239:54 amRNSForm 8.5 (EPT/RI)
8th Sep 20237:30 amRNSSuspension - Yourgene Health Plc
7th Sep 202311:46 amRNSCourt sanction of the Scheme of Arrangement
7th Sep 202310:10 amRNSForm 8.5 (EPT/RI)
5th Sep 202310:30 amRNSForm 8.5 (EPT/RI)
4th Sep 202310:01 amRNSForm 8.5 (EPT/RI)
1st Sep 20235:30 pmRNSYourgene Health
1st Sep 202312:07 pmRNSForm 8.5 (EPT/RI)
31st Aug 202310:58 amRNSForm 8.3 - Yourgene Health PLC
31st Aug 20239:42 amRNSForm 8.5 (EPT/RI)
30th Aug 20239:42 amRNSForm 8.5 (EPT/RI)
24th Aug 20239:27 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
23rd Aug 20239:50 amRNSForm 8.5 (EPT/RI)
23rd Aug 20239:24 amRNSForm 8.3 - Yourgene Health PLC
22nd Aug 20231:25 pmRNSHolding(s) in Company
22nd Aug 20239:01 amRNSForm 8.5 (EPT/RI)
21st Aug 20235:29 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 20232:12 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 202311:03 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
21st Aug 20237:02 amRNSForm 8.3 - Yourgene Health PLC
18th Aug 20233:09 pmRNSForm 8.3 - Yourgene Health plc
18th Aug 20231:28 pmRNSForm 8.5 (EPT/RI)
17th Aug 20235:03 pmRNSResult of Court Meeting and General Meeting
17th Aug 202310:13 amRNSForm 8.5 (EPT/RI)
16th Aug 20239:40 amRNSForm 8.5 (EPT/RI)
15th Aug 20234:41 pmRNSForm 8.5 (EPT/RI) Replacement
15th Aug 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Aug 202310:16 amRNSForm 8.5 (EPT/RI)
14th Aug 20239:20 amRNSForm 8.3 - Yourgene Health PLC
11th Aug 20231:12 pmRNSForm 8.3 - Yourgene Health plc
11th Aug 202310:10 amRNSForm 8.5 (EPT/RI)
10th Aug 202311:59 amRNSForm 8.5 (EPT/RI)
9th Aug 202310:12 amRNSForm 8.5 (EPT/RI)
8th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
8th Aug 202311:43 amRNSForm 8.5 (EPT/RI)
7th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
7th Aug 202311:56 amRNSForm 8.5 (EPT/RI)
4th Aug 20231:35 pmRNSForm 8.3 - Yourgene Health plc
4th Aug 202310:54 amRNSForm 8.5 (EPT/RI)
4th Aug 202310:47 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 202310:04 amRNSForm 8.5 (EPT/RI)
3rd Aug 20239:51 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 20239:19 amRNSForm 8.3 - YOURGENE HEALTH PLC
2nd Aug 20232:02 pmRNSForm 8.3 - Yourgene Health plc
2nd Aug 202310:21 amRNSForm 8.5 (EPT/RI)
1st Aug 20235:30 pmRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.